Articles: amyotrophic-lateral-sclerosis-pathology.
-
J. Neurol. Neurosurg. Psychiatr. · Nov 2015
Multicenter StudyTracking motor neuron loss in a set of six muscles in amyotrophic lateral sclerosis using the Motor Unit Number Index (MUNIX): a 15-month longitudinal multicentre trial.
Motor Unit Number Index (MUNIX) is a novel neurophysiological measure that provides an index of the number of functional lower motor neurons in a given muscle. So far its performance across centres in patients with amyotrophic lateral sclerosis (ALS) has not been investigated. ⋯ MUNIX is a reliable electrophysiological biomarker to track lower motor neuron loss in ALS.
-
To report MRI spinal changes after surgical infusion of bone marrow stem cells (BMSc) in ALS patients and assess their correlation with clinical events and functional performance. ⋯ Infusion of BMSc produces a variety of spinal changes apparently unrelated with clinical events and disease worsening.
-
Multicenter Study
Cortical atrophy in ALS is critically associated with neuropsychiatric and cognitive changes.
To characterize the patterns of brain atrophy in patients with amyotrophic lateral sclerosis (ALS) with and without cognitive and neuropsychiatric symptoms, in comparison to controls and patients with ALS-frontotemporal dementia (FTD). ⋯ The present findings establish that cortical atrophy in ALS is highly dependent upon neuropsychiatric and cognitive changes. Previous inconsistent findings of cortical atrophy in ALS likely relate to the inclusion of cognitively affected patients and patients with pure motor ALS.
-
Multicenter Study Comparative Study
Phase II screening trial of lithium carbonate in amyotrophic lateral sclerosis: examining a more efficient trial design.
To use a historical placebo control design to determine whether lithium carbonate slows progression of amyotrophic lateral sclerosis (ALS). ⋯ This study provided Class IV evidence that lithium carbonate does not slow the rate of decline of function in patients with ALS over 13 months.